Kanker-actueel Brain Tumors: Immunotherapy based on dendritic cells (stem cells) has shown in animal studies successfully in brain tumors - Glioblastoma. Article posted March 11, 2010

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

Dendritic Cell therapy and irradiation in addition to recommended by Belgian researchers Temodal for patients with brain tumors after good results from phase II study. Article posted 26 april 2012

Brain Tumors: glioblastoma dendritic cell specific peptides in patients with brain tumors appears to be successful. After three years, half of the patients were still alive compared to none in the control group. Article updated June 22, 2011

Brain Tumors: Complementary dendritic cell therapy after treatment of brain tumors with chemotherapy (Temodal) and radiation therapy appears promising. This shows small study with 10 patients with glioblastoma multiforme. Article updated April 24, 2011

Brain Tumors: Immunotherapy (IT-107) in the form of dendritic cell therapy shows excellent results in people with a brain tumor - glioblastoma multiforme. 80% alive after 2 years. From Phase I study. Article updated December 27, 2010

Brain Tumors: Dendritic cell therapy doubles survival time of people with a brain tumor glioblastoma multiforme for 31 months. Some have lived 8 years cancer free. According to a long-term phase II studies at the University of UCLA with 23 patients. Article posted March 23, 2011

Brain Tumors: Dendritic cell therapy for brain tumors (glioblastoma multiforme) gives remarkably good results. 11 of 16 patients (80% vs. 26.5%) were still alive after 2 years. For randomized phase II / III trial can now be registered. Be quick because only 100 patients to participate worldwide. Article updated January 22, 2011

Brain Tumors: Immunotherapy based on dendritic cells (stem cells) appears effective in animal studies in brain tumors - glioblastoma. Article posted March 11, 2010

Brain tumors and dendritic cell: DCVax (R) - brain vaccine, a type of dendritic cell therapy shows significant (more than double) longer overall survival and disease-free time. 33% are still alive after 4 years. 27% has been six years without a relapse in 2010. Article updated March 23, 2011

Brain tumors and dendritic cell: Dendritic cell therapy prior to operation of a recurrence of a glioblastoma multiforme disease-free time and greater overall survival, 14% survived 2 years. Article updated March 23, 2011

Brain Tumors: dendritic cell therapy in addition to Temodal provides children with a brain tumor for promising results. Thus study of University of Leuven. Article updated March 23, 2011

Brain Tumors: The Belgian physician Dr.. The Vleeschouwer reported a beneficial effect of vaccination of dendritic cells in patients with brain tumors - glioblastoma. In 23 patients doubled the survival time to relapse and a number of new patients have been cancer free after a few years to be injected with their own dendritic cells. Article updated March 25, 2010.

Brain tumors and dendritic cell: Dendritic cell therapy in a glioblastoma multiforme Grade IV indicates disease-free and significantly improved immune stimulation, thus small (32 patients) phase II study. Article updated April 24, 2011

Brain Tumors: Immunotherapy based on dendritic cells (stem cells) appears effective in animal studies in brain tumors - glioblastoma. Article posted March 11, 2010

June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning

And click here for addresses of clinics in Germany, where dendritic cell therapy is given .

March 11, 2010: Source: cellular immune Therapeutics, Ltd.

Immunotherapy based on dendritic cells - stem cells appears in a randomized preclinical study in rats with brain tumors - Glioblastoma effective. Or so says a press release from the producer of the investigational vaccine. The rats were divided into two groups. One group received a vaccine based on the removed tumor tissue. The other group received a vaccine based on stem cells (dendritic cells). The rats on the basis of the removed tumor tissue were immunized all died. 30% of the group of rats were treated with dendritic cell therapy using stem cells survived long term.

cellular immune Therapeutics "Dendritic Cell-Based Vaccine Demonstrates Statistically Significant Increase in Survival in an Animal Model of Glioblastoma

LOS ANGELES, March 10, 2010 (BUSINESS WIRE) - cellular immune Therapeutics, Ltd.. (OTC.BB: IMUC) Announced Today That its dendritic cell based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma. The rats were immunized Either with cancer stem cells (CSCs) from a brain tumor or cancer cells the daughter (the bulk of the tumor), and results showed That Those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. Further More, 30% of animals vaccinated against cancer stem cells demonstrated long-term survival as compared to animals vaccinated with the bulk of the tumor, all of Which died.

"We are excited by the study's results, as it Represents a significant step forward in the continued development of our cancer stem cell-based vaccines," said Dr.. Manish Singh, PhD., President and CEO or cellular immune therapeutics. "The data validates our research Further targeting CSCs Indicating That Has The Potential to be a highly effective method of treating cancers Various Artists." The data demonstrated Also Increased gamma-interferon levels in animals Treated with CSCs, Indicating an Increased immune response consistent with Increase in survival Further supporting the mechanism of action of this approach

The Company's recently completed Phase I trial of its lead cancer vaccination product candidate IT-107, an active immunotherapy Developed from studies conducted by immune cellular Therapeutics, showed That targeting 'certain specific antigens That are highly Expressed on cancer stem cells (CSCs) can lead to significant benefit in progression free survival as well as overall survival in GBM Patients